The Fgl2 prothrombinase contributes to the pathological process of experimental pulmonary hypertension.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of applied physiology"
DOI: 10.1152/japplphysiol.00396.2019
Abstract: In situ thrombus formation is one of the major pathological features of pulmonary hypertension (PH). The mechanism of in situ thrombosis has not been clearly identified. Fgl2 prothrombinase is an immune coagulant that can cleave… read more here.
Keywords: fgl2; fgl2 prothrombinase; situ thrombus; pulmonary hypertension ... See more keywords
Urokinase-loaded cyclic RGD-decorated liposome targeted therapy for in-situ thrombus of pulmonary arteriole of pulmonary hypertension
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Bioengineering and Biotechnology"
DOI: 10.3389/fbioe.2022.1038829
Abstract: Backgroud: In-situ thrombosis is a significant pathophysiological basis for the development of pulmonary hypertension (PH). However, thrombolytic therapy for in-situ thrombus in PH was often hampered by the apparent side effects and the low bioavailability… read more here.
Keywords: situ; therapy situ; therapy; situ thrombus ... See more keywords